Fed up with the low share price?, page-65

What about $2.50 and $2.00 why go so slow it's a good question though, from $2.50 the Viraleze ground to a halt in the UK and did not spread into EU pharmacies as expected yet it still remained available to buy in over 3 dozen countries then TGA decided to hold up approval yet launches and approvals continued for Viraleze Vietnam, Saudi Arabia etc, also Scripps continued to put out new impressive findings on Viraleze. So we can assume Viraleze has dragged the share price down yet couple years ago we had never heard of Viraleze and were invested in the company for what? DEP of course and to some degree vivagel. The DEP program has gone from strength to strength over this time ie AZD 4066, new partnerships with other big pharmas etc. So why the drag back to here? I don't know you tell me shorters have not helped other biotech disasters like msb did not help either. However fundamentals are still strong, catylists still wait around the corner, sales increase in BV and Viraleze continuing the future of this company still very strong and it is massively undervalued, negative posters, non holders and sky falling in chartists will not convince me or some others otherwise. Imo